Human Fc gamma RIIIA / CD16a (V176) Protein, His Tag (SPR & BLI & MALS verified)
分子別名(Synonym)
FCGR3A,CD16A,FCG3,FCGR3,IGFR3
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD16a (V176), His Tag (CD8-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1 (F176V)).
Predicted N-terminus: Gly 17
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.7 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景(Background)
CD16是一種低親和力的Fc受體,已被鑒定為Fc受體FcγRIIIa(CD16a)和FcγRIIIb(CD16b)。這些受體與IgG抗體的Fc部分結(jié)合。CD16由兩個不同的高度同源基因以細(xì)胞類型特異性方式編碼。CD16存在于自然殺傷細(xì)胞,中性粒細(xì)胞多形核白細(xì)胞,單核細(xì)胞和巨噬細(xì)胞的表面。
CD16a抗原也稱為低親和力免疫球蛋白γFc區(qū)受體III-A,FcγRIIIα。CD16b是由嗜中性粒細(xì)胞和嗜酸性粒細(xì)胞表達(dá)的低親和力GPI連接受體,而CD16a是中等親和力多肽錨定的跨膜糖蛋白表達(dá)的自然殺傷細(xì)胞,巨噬細(xì)胞,T細(xì)胞亞群,未成熟胸腺細(xì)胞和胎盤滋養(yǎng)細(xì)胞。CD16a參與吞噬作用,酶和炎癥介質(zhì)的分泌,抗體依賴性細(xì)胞毒性和免疫復(fù)合物的清除。CD16a的異常表達(dá)或突變與復(fù)發(fā)性病毒感染,系統(tǒng)性紅斑狼瘡和同種免疫新生兒中性粒細(xì)胞減少癥的易感性有關(guān)。
關(guān)鍵字: FCGR3A;FCGR3A蛋白;CD16A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。